SCHEMBL13077831

SCHEMBL13077831

Cc1ccc(S(=O)(=O)NCC/C=C/CN[C@H](C)c2cccc3ccccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASR P41180 2/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPY5R Q15761 1/20 0.41
▸ CYP19A1 P11511 2/20 0.40
▸ HMOX1 P09601 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13077911 0.90 BMP1 (0.49) CASRALDH1A1CYP3A4CYP2D6CYP2C19
SCHEMBL13077963 0.85 CASR (0.42) CASRMEN1KMT2ACYP2D6
SCHEMBL13040850 0.84 CASR (0.40) CASRMEN1KMT2ACYP1A2CYP3A4
SCHEMBL13041022 0.83 CASR (0.39) CASRMEN1KMT2AALDH1A1CYP1A2
SCHEMBL13077566 0.82 CASR (0.40) CASRCYP2D6
SCHEMBL13078021 0.80 CASR (0.41) CASRCYP2D6
SCHEMBL13077622 0.79 CASR (0.43) CASRCYP2D6
SCHEMBL13077812 0.78 CASR (0.43) CASRCYP2D6
SCHEMBL13077822 0.76 CASR (0.48) CASRMEN1KMT2AALDH1A1CYP2D6
SCHEMBL13077959 0.76 CASR (0.41) CASRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 — — US disclosed
WO-2008019690-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R CASR 5/4885MEN1 202/4885KMT2A 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback